Source: BioSpace
Area: News
BioSpace has reported on the results of an integrated analysis of two Phase III studies (VIEW 1 and VIEW 2) of aflibercept intravitreal injection in the treatment of neovascular age-related macular degeneration (wet AMD). The 52-week results from the studies have previously been reported; the current data are from a further analysis at 96 weeks.
Posts Tagged ‘ anti-VEGF ’
VEGF-Trap Gets Closer to FDA Approval
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received priority review status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10 month period. Alfibercept is another injectable drug that may have an effect on choroidal neovascularization in wet macular degeneration.
CATT Study Update 12: Status of WorldWide Studies
With the anticipated arrival of the one-year results of the CATT Study this Spring, I thought it would be appropriate to update where the other worldwide studies stand.
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in CRVO and in Phase 2 Study in DME
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with m...
Avastin/Lucentis Update 44: United Kingdom Closer to Allowing Avastin for AMD
While the U.S. comes closer to showing the equivalency of Avastin to Lucentis for treating the wet form of age-related macular degeneration, when the CATT Study (Comparisons of Age-Related Macular Degeneration Treatments Trials) results become public, hopefully, some time this Spring, the UK’s health services are still fighting over whether or not they should study the two drugs to determine if Avastin would be appropriate for the Brits to use in their National Health Service.
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: 1-year Outcomes of a Prospective, Double-masked Randomised Clinical Trial
This study compares two drugs in the treatment of age-related macular degeneration.
Eye
Eye
How Effective Are AMD Drugs in Treating Diabetic Macular Edema?
At the AAO meeting in October, researchers reported that anti-VEGF drugs such as ranibizumab (Lucentis) and pegaptanib (Macugen) also appeared to be effective in improving visual acuity in patients with diabetic macular edema in a series of randomized, controlled trials.
Cochrane Review Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular edema (ME) may develop, with a consequent reduction in visual acuity. The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especially those with the ischemic subtype, and until recently there has been no treatment of proven benefit. Macular grid laser treatment is ineffective, and whilst a few recent randomized controlled trials (RCTs) suggest short-term gains in visual acuity with intravitreal steroids for patients with non-ischemic CRVO-ME, there is no established treatment for ischemic CRVO-ME. Anti-vascular endothelial growth factor (anti-VEGF) agents have been used to treat ME resulting from a variety of causes and may represent a treatment option for CRVO-ME.
Lucentis receive DME approval in EU
(Ophtalmology Times Europe)
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).
Full Story ->
Avastin Intravitreal Bevacizumab Genentech Inc for treatment of choroidal neovascularization secondary to pathological myopia
New abstract in the Health Technology Assessment (HTA) Database from the Centre for Reviews and Dissemination.
Do Anti-VEGF Injections Increase the Risk of Stroke or Heart Attack?
Some have speculated that the anti-VEGF injections we give to macular degeneration patients may get into the bloodstream and have adverse vascular effects. According to a recently released retrospective study (appearing in the October 2010 issue of the Archives of Ophthalmology), using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related macular degeneration does not appear to increase the risk of (Read more...)
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
New Cochrane review issued on 6th October 2010.
Subscribe
